Claims

1. A compound of Formula (III):



Formula III

or a pharmaceutically acceptable salt thereof, wherein:

R^2 is C_1-C_6 alkoxy or C_6-C_{10} aryloxy substituted with 1-3 R^6;

R^3 is C_2-C_6 hydroxyalkyl or C_1-C_6 heteroalkyl;

R^4 is C_1-C_6 alkyl;

R^6 is independently C_1-C_6 alkyl, halo, C_1-C_6 haloalkyl, C_1-C_6 haloalkoxy or C_1-C_6 alkoxy;

each R^a is C_1-C_6 alkyl, C_1-C_6 haloalkyl or halo;

n is 1 or 2; and

m is 1, 2, or 3.

2. A compound selected from the group consisting of:



,



,



,





, , ,





, , ,





, ,





, , ,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



.



,



,



,



,



,



,



,



,



,



,



,



,



,





,

,

,





,

,

,





,

,

,





,

,

,



,



,



,



,



,



,



,



,



,



,



,



,


,

,

,


,

,

,


,

,

,


,

,

,


,

,

,


,

,

,


,

,

,


,

,

,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,





,

,

,





,

,

,





,

,

,





,

,

,



,



,



,



,



,



,



,



,



,



,



,



,


,

,

,

,

,

,

,

,

,

,

,

,


,

,

,


,

,

,


,

,

,


,

,

,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,


,

,

,

,

,

,

,

,

,

,

,

,



,



,



,



,



,



,



,



,



,



,



,



,





,

,

,





,

,

,





,

,

,





,

,

,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,


,

,

,

,

,

,

,

,

,

,

,

,


















,

,

,


,

,

,


,

,

,


,

,

,



,



,



,



,



,



,



,



,



,



,



,



,


,

,

,

,

,

,

,

,

,

,

,

,


















,

,

,


,

,

,


,

,

,


,

,

,


,

,

,


,

,

,


,

,

,


,

,

,



,



,



,



,



,



,



,



,



,



,



,



,


,

,

,


,

,

,


,

,

,


,

,

,



,



,



,



,



,



,



,



,



,



,



,



,





, , ,





, , ,





, , ,


, 
and


.

3. The compound according to claim 1 or 2 having the structure:



or a pharmaceutically acceptable salt thereof.

4. The compound according to claim 1 or 2 having the structure:



or a pharmaceutically acceptable salt thereof.

5. The compound according to claim 1 or 2 having the structure:



or a pharmaceutically acceptable salt thereof.

6. The compound according to claim 1 or 2 having the structure:



or a pharmaceutically acceptable salt thereof.

7. The compound according to claim 2 having the structure:



or a pharmaceutically acceptable salt thereof.

8. A pharmaceutical composition comprising a compound according to any of the preceding claims, or a pharmaceutically acceptable salt thereof.

9. A compound or a pharmaceutical composition according to any of the preceding claims for use in the treatment of a disorder selected from the group consisting of: neuropsychiatric disorder, neurodegenerative disorder, nephropathy, and seizure disorder.